We've known for decades that frequencies are an excellent approach to
treating cancer with dramatically less side effects than chemotherapy
and radiation. It is nice to finally see a group do a successful
clinical trial on this.

This team did not even use frequencies in the range known to kill
cancer cells and were successful. Image what they could if they
utilized the expertise in the worldwide community working with this
technology!

An important finding (pointed out for many years on this site) is that
frequencies are specific to specific cells and cell types. This makes
it challenging for the average university research groups. As Rife has
shown us, getting the exact frequencierequires painstaking work for
many years with highly refined tools not generally available.

Also well known, and can be inferred by the data in this study, is that
it is difficult to eliminate cancer completely for terminal cases, but
possible to signficantly increase the life span and quality of life
compared to conventional treatment.
------

Amplitude-modulated electromagnetic fields for the treatment of cancer:
Discovery of tumor-specific frequencies and assessment of a novel
therapeutic approach
Alexandre Barbault, Frederico P Costa , Brad Bottger , Reginald F
Munden , Fin Bomholt , Niels Kuster and Boris Pasche
Cabinet Médical, Avenue de la Gare 6, Lausanne, Switzerland
Rue de Verdun 20, Colmar, FranceSirio-Libanes Hospital, Oncology
Center, São Paulo, Brazil
Radiology Associates, Danbury Hospital, Danbury, CT, USA
5Department of Radiology, The University of Alabama at Birmingham and
UAB Comprehensive Cancer Center, Birmingham, AL, USA
SPEAG AG, Zurich, Switzerland
IT'IS, Swiss Federal Institute of Technology, Zurich, Switzerland
Division of Hematology/Oncology, Department of Medicine, The University
of Alabama at Birmingham and UAB Comprehensive Cancer Center,
Birmingham, AL, USA

Journal of Experimental & Clinical Cancer Research 2009,
28:51doi:10.1186/1756-9966-28-51

The electronic version of this article is the complete one and can be
found online at: http://www.jeccr.com/content/28/1/51

Received: 8 January 2009
Accepted: 14 April 2009
Published: 14 April 2009
© 2009 Barbault et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.

Abstract

Purpose
Because in vitro studies suggest that low levels of electromagnetic
fields may modify cancer cell growth, we hypothesized that systemic
delivery of a combination of tumor-specific frequencies may have a
therapeutic effect. We undertook this study to identify tumor-specific
frequencies and test the feasibility of administering such frequencies
to patients with advanced cancer.

Patients and methods
We examined patients with various types of cancer using a noninvasive
biofeedback method to identify tumor-specific frequencies. We offered
compassionate treatment to some patients with advanced cancer and
limited therapeutic options.

Results
We examined a total of 163 patients with a diagnosis of cancer and
identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz.
Most frequencies (57–92%) were specific for a single tumor type.
Compassionate treatment with tumor-specific frequencies was offered to
28 patients. Three patients experienced grade 1 fatigue during or
immediately after treatment. There were no NCI grade 2, 3 or 4
toxicities. Thirteen patients were evaluable for response. One patient
with hormone-refractory breast cancer metastatic to the adrenal gland
and bones had a complete response lasting 11 months. One patient with
hormone-refractory breast cancer metastatic to liver and bones had a
partial response lasting 13.5 months. Four patients had stable disease
lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1
months (non-small cell lung cancer), 4.1 months (pancreatic cancer
metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to
liver).

Conclusion
Cancer-related frequencies appear to be tumor-specific and treatment
with tumor-specific frequencies is feasible, well tolerated and may
have biological efficacy in patients with advanced cancer.

Trial registration
clinicaltrials.gov identifier NCT00805337

--
Posted By Jeff Sutherland to Dr. Jeff Sutherland's Electronic Medicine
at 9/10/2009 06:03:00 PM